Biogen - Биоген - Photos | Facebook
UPDATE: Sandrock makes a sharp exit, retiring as Biogen R&D chief amid fallout from Aduhelm approval | Fierce Biotech
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Biogen doubles up on deals for small molecules
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug | Barron's
Biogen-C | Rachael Rosewood Skin Clinic
Under-pressure Biogen aims to please restive investors with bigger, better board | Fierce Pharma
Biogen Stock Flies On Upgrade; Why Alzheimer's Is A $7 Billion Opportunity | Investor's Business Daily
Biogen, at a Crossroads, Surges on Promising Alzheimer's Drug Assessment - WSJ
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst | Fierce Pharma
Code of Business Conduct | Biogen
Home | Biogen
Biogen shares soar after patent victory | Financial Times
Biogen Foundation | Biogen
Biogen Foundation | Biogen
Home | Biogen
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug | Fierce Biotech
Pipeline | Biogen
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
Biogen's stock rises 3% after releasing new data on late-stage Alzheimer's drug
Broad scales up as Biogen scales back in Kendall Square - The Boston Globe
Company | Biogen
Home | Biogen
Biogen and Alcyone Therapeutics partner up for novel device for neurological ASO therapies
Biogen - Wikipedia
Biogen bags Karyopharm neurological drug in $217M deal | Fierce Biotech
